DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Maio M, Scherpereel A, Calabro L. et al.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol 2017;
18: 1261-1273
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.